Medtronic PLC

MDT remains in an early Stage 1 consolidation with short-term EMAs repaired and a recent Momentum Breakout signaling demand. However, price is extended above rising EMAs and prior resistance without visible exhaustion, warranting patience. A pullback into the 9/21 EMA zone and pivot support area offers the optimal entry for the medium-term bullish bias.

• ↑Q4 FY26 revenue of $9.8B (+9.9% YoY); FY27 organic growth guided at 6.75–7.25%.
• ↑CAS segment revenue up 78% YoY aided by strong procedural demand.
• ↓Weak profitability with low margins and poor returns on revenue.